Market sizing is a foundational component of private equity diligence, shaping how investors assess growth potential, competitive positioning, and the ultimate scalability of a platform. Yet in healthcare services and life sciences, estimating the true size of a market is rarely straightforward. Market sizing exercises are often among the most debated aspects of an investment thesis, with deal teams frequently grappling with whether the numbers truly reflect underlying demand and utilization.

Analysis of healthcare markets presents a unique set of methodological challenges that can materially distort market size estimates. Common pitfalls include misinterpreting claims data, conflating disease incidence with service utilization, confusing current / serviceable markets with total addressable markets, and failing to account for policy dynamics that can rapidly reshape market behavior and trends.

In this whitepaper, Marwood examines some common sources of error in healthcare market sizing through a series of case studies that illustrate how analytical assumptions can meaningfully alter perceived market opportunity. The article concludes with three best practices for investors and executives seeking to develop more robust and defensible analysis of healthcare services and life sciences market opportunities.